John Marshall, MD, presents the Avastin MCRC pivotal trials.
Dr. John Marshall received a consultation fee from Genentech for sharing his opinion and treatment practices with Avastin.
Avastin, in combination with intravenous 5‑fluorouracil-based chemotherapy, is indicated for the first‑ or second‑line treatment of patients with metastatic colorectal cancer.
Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second‑line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin-containing regimen.
Limitation of Use: Avastin is not indicated for adjuvant treatment of colon cancer.
Additional serious adverse events
Most common adverse events
Indication-specific adverse events
You may report side effects to the FDA at (800) FDA-1088 orwww.fda.gov/medwatch.
You may also report side effects to Genentech at (888) 835-2555.
Please see accompanying full Prescribing Information, includingBoxed WARNINGS, for additional important safety information.